rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Craig A. Wheeler

Director

Company insider

Files Form 4 as: Director, Apellis Pharmaceuticals; Director, Amicus Therapeutics; President & CEO, Momenta Pharmaceuticals; Director, Avanir Pharmaceuticals; V.P.; Pres., Chiron BioPharma, Chiron.

Every Form 4 they filed

In numbers

Trades disclosed
428
Buys
0
Sells
160
Bought
$0
Sold
$29.6M
Companies
5
Companies where not an officer
3
First trade
13 Feb 2006
Last trade
14 May 2026
Last filed
14 May 2026

Companies traded

Where they are an officer
Momenta PharmaceuticalsDirector, Officer · last 1 Oct 20200 buys · 160 sells
ChironOfficer · last 19 Apr 20060 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Apellis PharmaceuticalsDirector · Biotechnology · last 14 May 20260 buys · 0 sells
Amicus TherapeuticsDirector · Biotechnology · last 27 Apr 20260 buys · 0 sells
Avanir PharmaceuticalsDirector · last 12 Feb 20140 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
14 May 2026filed 14 May 2026Apellis PharmaceuticalsBiotechnologySEC FORM 4 Code U—24,444filing
14 May 2026filed 14 May 2026Apellis PharmaceuticalsBiotechnologySEC FORM 4 Code D—15,110filing
14 May 2026filed 14 May 2026Apellis PharmaceuticalsBiotechnologySEC FORM 4 Code D—7,961filing
14 May 2026filed 14 May 2026Apellis Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—28,195filing
14 May 2026filed 14 May 2026Apellis Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—14,684filing
14 May 2026filed 14 May 2026Apellis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—28,195filing
14 May 2026filed 14 May 2026Apellis Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—14,684filing
14 May 2026filed 14 May 2026Apellis PharmaceuticalsSEC FORM 4 Code U—24,444filing
14 May 2026filed 14 May 2026Apellis PharmaceuticalsSEC FORM 4 Code D—15,110filing
14 May 2026filed 14 May 2026Apellis PharmaceuticalsSEC FORM 4 Code D—7,961filing
27 Apr 2026filed 27 Apr 2026Amicus TherapeuticsBiotechnologySEC FORM 4 Code D$1.2M84,631 at $14.50filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—74,872filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—30,000filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—16,236filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—30,000filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—16,236filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—19,473filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—18,574filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—36,111filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—45,423filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed160

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.